Cutera (CUTR) Downgraded by TheStreet

TheStreet downgraded shares of Cutera (NASDAQ:CUTR) from a b- rating to a c+ rating in a report published on Tuesday morning.

Other research analysts have also recently issued research reports about the company. Gabelli reiterated a buy rating on shares of Cutera in a research note on Friday, February 16th. ValuEngine lowered Cutera from a strong-buy rating to a buy rating in a report on Wednesday, May 9th. BidaskClub lowered Cutera from a strong-buy rating to a buy rating in a report on Thursday, March 29th. Zacks Investment Research lowered Cutera from a strong-buy rating to a hold rating in a report on Wednesday, April 18th. Finally, Stifel Nicolaus assumed coverage on Cutera in a report on Monday, April 16th. They issued a hold rating and a $55.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $46.67.

Cutera opened at $40.00 on Tuesday, Marketbeat.com reports. Cutera has a one year low of $37.65 and a one year high of $38.20. The stock has a market capitalization of $517.43 million, a P/E ratio of 51.95, a price-to-earnings-growth ratio of 1.59 and a beta of 0.48.

Cutera (NASDAQ:CUTR) last released its quarterly earnings results on Tuesday, May 8th. The medical device company reported ($0.02) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.01 by ($0.03). Cutera had a return on equity of 16.12% and a net margin of 18.54%. The business had revenue of $34.10 million during the quarter, compared to analyst estimates of $35.27 million. During the same quarter last year, the firm posted ($0.07) EPS. The company’s revenue was up 16.4% compared to the same quarter last year. analysts forecast that Cutera will post 0.57 EPS for the current year.

In related news, insider James A. Reinstein bought 2,800 shares of the stock in a transaction dated Friday, May 11th. The stock was bought at an average cost of $35.55 per share, with a total value of $99,540.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gregory A. Barrett bought 5,450 shares of the stock in a transaction dated Friday, May 11th. The shares were bought at an average cost of $36.98 per share, with a total value of $201,541.00. The disclosure for this purchase can be found here. 11.60% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. grew its holdings in shares of Cutera by 74.5% during the third quarter. Schwab Charles Investment Management Inc. now owns 32,648 shares of the medical device company’s stock valued at $1,350,000 after purchasing an additional 13,943 shares during the last quarter. Two Sigma Investments LP grew its holdings in shares of Cutera by 25.5% during the fourth quarter. Two Sigma Investments LP now owns 68,177 shares of the medical device company’s stock valued at $3,092,000 after purchasing an additional 13,862 shares during the last quarter. Texas Permanent School Fund bought a new position in shares of Cutera during the fourth quarter valued at approximately $425,000. Rhumbline Advisers grew its holdings in shares of Cutera by 110.3% during the fourth quarter. Rhumbline Advisers now owns 29,170 shares of the medical device company’s stock valued at $1,323,000 after purchasing an additional 15,300 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new position in shares of Cutera during the fourth quarter valued at approximately $379,000. 96.26% of the stock is owned by institutional investors.

About Cutera

Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.

Analyst Recommendations for Cutera (NASDAQ:CUTR)

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit